Xeris Biopharma Holdings, Inc.
XERSHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeXeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company carries a $1.09B market cap, placing it firmly in the small-cap category. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Market Cap
$1.09B
Beta
0.92
P/E (TTM)
90.29
P/E (Fwd)
16.00
EPS (TTM)
$0.07
EPS (Fwd)
$0.40
ROE
—
ROA
6.3%
Cash
$111.8M
Total Debt
$258.6M
Free CF
$42.2M
52W Change
27.9%
Annual Financials
Cash vs Debt
On the balance sheet, XERS has $111.8M in cash with $258.6M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $42.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. An ROA of 6.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $110.2M (2022) to $291.8M (2025), reflecting a 165% increase over the period.
At over 50x earnings, XERS carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. No single metric tells the full story. Reviewing XERS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.